COMMUNIQUÉS West-GlobeNewswire

Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
20/05/2026
Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra ® (resmetirom) Analysis of two-year data in patients with [...]
Prenetics Announces Jay Shetty as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
20/05/2026
Multi-year partnership lands as Prenetics’ IM8 raises full-year 2026 revenue guidance to $190 million to $210 million following nearly 6x year-over-year growth in Q1 2026 Shetty is IM8’s first global ambassador from [...]
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
20/05/2026
Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26 MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a [...]
Sustainability Leader Ashley McKeon Selected as Soil Health Institute’s President and CEO
20/05/2026
MORRISVILLE, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Ashley McKeon, a seasoned agriculture and sustainability executive, will lead the Soil Health Institute (SHI) into its next decade. McKeon, who previously led [...]
Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway
20/05/2026
MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq ® technology, marking a [...]
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid
20/05/2026
Seasoned biopharmaceutical leaders bring significant clinical development, financial and strategic expertise to support BlossomHill's next phase of growth SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- BlossomHill [...]
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
20/05/2026
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary [...]
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
20/05/2026
Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Segment also discusses evolving treatment landscape, immunologically “cold” tumors [...]
Aeroflow Urology Donates to National Diaper Bank Network and United Way to Improve National Health Equity
20/05/2026
Gifts to both organizations reflect Aeroflow Urology’s continuous commitment to community partnerships that directly support underserved families ASHEVILLE, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Aeroflow Urology , a [...]
Alzheimer’s Research Sites Honor National Clinical Trials Day
20/05/2026
Free Memory Screenings Offered to Promote Importance of Brain Health WASHINGTON, May 20, 2026 (GLOBE NEWSWIRE) -- Alzheimer’s research sites across the country are honoring National Clinical Trials Day by offering free [...]
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
20/05/2026
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will [...]
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
20/05/2026
31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstracts Independent [...]
Vistin Pharma ASA: Minutes from the annual general meeting 2026
20/05/2026
Oslo, Norway, 20 May 2026 Vistin Pharma ASA (OSE: VISTN), please find attached the minutes from the annual general meeting held today, on the 20 May 2026. Attachment Minutes from AGM Vistin Pharma ASA_20_May_2026
Disclosure of voting rights at AGM in Vistin Pharma ASA
20/05/2026
Oslo, Norway, 20 May 2026 In relation to the Annual General Meeting in Vistin Pharma ASA (OSE: VISTN), on the 20th of May, the Company's Chair of the Board, Øyvin Brøymer, has received open proxies to represent a total [...]
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
20/05/2026
Urges Stockholders to Vote “ FOR ” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company [...]
Winner Medical Breaks Ground on New Production Base in Vietnam to Serve Global Medical Supply Chains Through Local Manufacturing
20/05/2026
SHENZHEN, China, May 20, 2026 (GLOBE NEWSWIRE) -- Winner Medical has officially broken ground on its new manufacturing base in Hai Ha Industrial Park, Quang Ha Commune, Quang Ninh Province, Vietnam. With a total [...]
Largest-ever Canadian clinical trial tests “poop pills” to improve immunotherapy for lung cancer
20/05/2026
Backed by the Canadian Cancer Society and Weston Family Foundation, the LUNA-2 microbiome capsule research study will be the largest of its kind in Canada LONDON, Ontario, May 20, 2026 (GLOBE NEWSWIRE) -- For nearly [...]
Un essai clinique canadien sans précédent évalue des « comprimés de selles » pour améliorer l’immunothérapie du cancer du poumon
20/05/2026
Financée par la Société canadienne du cancer et la Fondation de la famille Weston, l’étude de recherche LUNA-2 sur les capsules de microbiome sera la plus vaste du genre au Canada LONDON, Ontario, 20 mai 2026 (GLOBE [...]
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
20/05/2026
Initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); submission expected to be completed in [...]

Pages